Abstract
The emergence of mutations that confer drug resistance in patients with chronic hepatitis B (CHB) is increasing in China. We aimed to compare the cumulative efficacy and resistance of adefovir (ADV) monotherapy and ADV add-on lamivudine (LAM) (ADV+LAM) therapy in LAM-resistant patients. One-hundred adult CHB patients with LAM-resistance mutations were identified. Of these 100, 52 patients were treated with ADV monotherapy and 48 were treated with ADV+LAM combination therapy for at least 24 months. After 2-year treatment, the cumulative rates of serum alanine aminotransferase normalization were, respectively, 73.1 and 83.3 % in the ADV monotherapy and ADV+LAM therapy groups (P = 0.216). Additionally, 36 patients receiving ADV plus LAM had hepatitis B e antigen loss/seroconversion, as compared with 30 in patients (P = 0.068). More patients who received LAM plus ADV than those who received ADV alone had HBV DNA levels below 1,000 international unit/milliliters (83.3 vs. 50 %, P < 0.001). Viral breakthrough and genotypic mutations were detected in 19 (36.5 %) and 9 (18.8 %) patients in the ADV monotherapy and ADV+LAM therapy groups, respectively (P = 0.048). ADV+LAM combination therapy demonstrated faster and significantly greater suppression of HBV DNA compared with ADV therapy alone for patients with LAM-resistance mutations. ADV+LAM was superior to ADV monotherapy in achieving the initial viral breakthrough and genotypic mutations. ADV+LAM combination therapy was rational for most of LAM-resistant Chinese patients with chronic hepatitis B.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
W. Lee, N. Engl. J. Med. 337, 1733–1745 (1997). doi:10.1056/NEJM199712113372406
R.J. Fontana, H.W. Hann, R.P. Perrillo, J.M. Vierling, T. Wright, J. Rakela, G. Anschuetz, R. Davis, S.D. Gardner, N.A. Brown, Gastroenterology (2002). doi:10.1053/gast.2002.35352
D. Ganem, A.M. Prince, N. Engl. J. Med. (2004). doi:10.1056/NEJMra031087
A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, E.R. Schiff, J.L. Dienstag, E.J. Heathcote, N.R. Little, D.A. Griffiths, S.D. Gardner, M. Castiglia, Gastroenterology (2003). doi:10.1053/j.gastro.2003.09.033
J.H. Lee, J.H. Yoon, E.J. Cho, H.J. Yang, E.S. Jang, M.S. Kwak, S.Y. Hwang, S.J. Yu, C.H. Lee, Y.J. Kim, C.Y. Kim, H.S. Lee, J. Clin. Gastroenterol. (2012). doi:10.1097/MCG.0b013e318225f559
R.P. Perrillo, H.W. Hann, E. Schiff, D. Mutimer, B. Willems, N. Leung, W.M. Lee, S. Dixon, M. Woessner, C.L. Brosgart, L.D. Condreay, S.D. Gardner, Hepatol. Int. (2011). doi:10.1007/s12072-010-9228-9
J.M. Lee, H.J. Kim, J.Y. Park, C.K. Lee, Y. Do Kim, J.K. Kim, H.W. Lee, Y.H. Paik, K.S. Lee, K.H. Han, C.Y. Chon, S.P. Hong, T. Nguyen, S.H. Ahn, Antivir Ther 14, 705–712 (2009)
C.Y. Dai, W.L. Chuang, M.Y. Hsieh, L.P. Lee, J.F. Huang, N.J. Hou, Z.Y. Lin, S.C. Chen, M.Y. Hsieh, L.Y. Wang, J.F. Tsai, W.Y. Chang, M.L. Yu, Antiviral Res. (2007). doi:10.1016/j.antiviral.2007.02.003
A.S. Lok, B.J. McMahon, Hepatology (2007). doi:10.1002/hep.21513
Z.L. Fang, C.A. Sabin, B.Q. Dong, S.C. Wei, Q.Y. Chen, K.X. Fang, J.Y. Yang, X.Y. Wang, T.J. Harrison, J. Hepatol. (2009). doi:10.1016/j.jhep.2008.09.014
M.G. Ghany, E.C. Doo, Hepatology (2009). doi:10.1002/hep.22900
F. Zoulim, M. Buti, A.S. Lok, J Viral Hepat (2007). doi:10.1111/j.1365-2893.2007.00915.x
S. Gaia, V. Barbon, A. Smedile, A. Olivero, S. Carenzi, M. Lagget, C. Alessandria, M. Rizzetto, A. Marzano, J. Hepatol. (2008). doi:10.1016/j.jhep.2007.12.018
S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S.G. Lim, Z. Goodman, J. Ma, C.L. Brosgart, K. Borroto-Esoda, S. Arterburn, S.L. Chuck, Gastroenterology (2006). doi:10.1053/j.gastro.2006.09.020
I. Carey, P.M. Harrison, Expert Opin. Investig. Drugs (2009). doi:10.1517/13543780903241599
E.Q. Chen, L.C. Wang, J. Lei, L. Xu, H. Tang, Virol. J. (2009). doi:10.1186/1743-422X-6-163
I. Rapti, E. Dimou, P. Mitsoula, S.J. Hadziyannis, Hepatology (2007). doi:10.1002/hep.21534
G.E. Chung, W. Kim, K.L. Lee, S.Y. Hwang, J.H. Lee, H.Y. Kim, Y.J. Jung, D. Kim, J.B. Jeong, B.G. Kim, Y.J. Kim, J.H. Yoon, H.S. Lee, Dig. Dis. Sci. (2011). doi:10.1007/s10620-010-1561-2
H.J. Kim, J.H. Park, D.I. Park, Y.K. Cho, C.I. Sohn, W.K. Jeon, B.I. Kim, J. Gastroenterol. Hepatol. (2010). doi:10.1111/j.1440-1746.2010.06381.x
A.S. Lok, B.J. McMahon, Hepatology (2009). doi:10.1002/hep.23190
G.V. Papatheodoridis, S. Manolakopoulos, J. Hepatol. (2009). doi:10.1016/j.jhep.2009.02.017
Acknowledgments
This work was supported by a Grant from the National Clinical Key Specialty Construction Projects to the Department of Clinical Laboratory of Renmin Hospital of Wuhan University.
Conflict of interest
The authors have declared that no competing interest exists.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, M., Yuan, L., Qiao, B. et al. Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudine. Virus Genes 48, 32–37 (2014). https://doi.org/10.1007/s11262-013-1004-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11262-013-1004-1